Welcome!

News Feed Item

Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

The study, titled, A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer, evaluated the association of ChemoFx® results with disease progression for 276 FIGO stage III-IV ovarian, fallopian and peritoneal cancer patients treated with the standard of care first-line therapy carboplatin/paclitaxel. Patients whose tumors were scored as resistant by the ChemoFx test to carboplatin, were at significantly increased risk of disease progression compared to those with non-resistant tumors (median PFS: 11.8 vs. 16.6 months, respectively, p<0.001). The association was confirmed after adjusting for other clinical factors (HR=1.71, 95% CI=1.12-2.62, p=0.013). In addition to identifying platinum-resistant patients, the study also demonstrated the ability of ChemoFx to identify agents to which a patient’s tumor is sensitive. For 59% of those patients whose tumors proved resistant to carboplatin, at least one other commonly utilized agent was determined by ChemoFx to be sensitive or intermediately sensitive, indicating that these patients may benefit from alternative clinically validated treatments. These results further demonstrate the capability of the ChemoFx test to inform treatment decisions beyond the carboplatin/paclitaxel standard of care, particularly in cases where patients are unlikely to respond to the routine treatment.

Dr. Thomas C. Krivak, M.D., assistant director of gynecologic oncology and director of clinical research in gynecologic oncology at Allegheny Health Network, Department of Obstetrics and Gynecology, in Pittsburgh PA, is the primary author of the study.

“What the findings of this study essentially mean for ovarian cancer patients is that resistance to standard platinum chemotherapy treatment can now be determined much earlier in the treatment pathway with the use of ChemoFx results,” said Dr. Krivak. “Earlier determination of platinum resistance may help physicians choose the more effective treatments upfront, minimizing exposure to ineffective and often expensive therapy. Additionally, having further information about the tumor and chemotherapy resistance could substantiate augmenting standard of care with a third chemotherapy or with targeted agents.”

In addition to these findings, a recent, prospective study on recurrent ovarian cancer patients showed a 14 month improvement in median overall survival when patients were administered treatments identified as sensitive by ChemoFx vs. the non-sensitive treatments. “The combination of information this test provides is invaluable to physicians who are compelled to choose from a range of equivalent treatment recommendations without prior knowledge of how an individual patient may respond to any given treatment,” said Sean McDonald, CEO of Precision. “The ability of this test to determine platinum resistance in primary ovarian cancer patients and to demonstrate longer overall survival by 14 months in recurrent ovarian cancer, makes it an instrumental tool in helping to improve outcomes in ovarian cancer patients.”

About ChemoFx®

ChemoFx® is a proprietary drug response marker, which categorizes an individual patient’s tumor response to a range of standard chemotherapeutic options. Recently published prospective data demonstrates a 14-month improvement in overall survival (OS) when recurrent ovarian cancer patients are treated with therapy indicated as ‘responsive’ by the assay. ChemoFx may also help identify platinum-resistant/refractory primary ovarian patients earlier in their treatment pathway, aiding physicians with the selection of effective treatment upfront for patients newly diagnosed. Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalizing cancer care and improving patient outcomes. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s other leading products for personalized cancer care include:

  • BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
  • GeneFx® Colon, an expression–based gene signature developed for FFPE tissue from stage II colon cancer patients. Following surgery, GeneFx Colon assesses a patient’s risk of recurrence within 5 years.

For more information, visit www.precisiontherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are an IT services solution provider and we sell software to support those solutions. Our focus and key areas are around security, enterprise monitoring, and continuous delivery optimization," noted John Balsavage, President of A&I Solutions, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"DivvyCloud as a company set out to help customers automate solutions to the most common cloud problems," noted Jeremy Snyder, VP of Business Development at DivvyCloud, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We provide IoT solutions. We provide the most compatible solutions for many applications. Our solutions are industry agnostic and also protocol agnostic," explained Richard Han, Head of Sales and Marketing and Engineering at Systena America, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We want to show that our solution is far less expensive with a much better total cost of ownership so we announced several key features. One is called geo-distributed erasure coding, another is support for KVM and we introduced a new capability called Multi-Part," explained Tim Desai, Senior Product Marketing Manager at Hitachi Data Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
SYS-CON Events announced today that Calligo, an innovative cloud service provider offering mid-sized companies the highest levels of data privacy and security, has been named "Bronze Sponsor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Calligo offers unparalleled application performance guarantees, commercial flexibility and a personalised support service from its globally located cloud plat...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.